These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21709491)

  • 21. Disposal of therapeutic 131I waste using a multiple holding tank system.
    Leung PM; Nikolic M
    Health Phys; 1998 Sep; 75(3):315-21. PubMed ID: 9721842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
    de Carvalho JW; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C
    Nucl Med Commun; 2009 Jul; 30(7):533-41. PubMed ID: 19436231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Labelled amino acids in plasma of patients with thyrotoxicosis and thyroid cancer after radioiodine treatment.
    Bednár J; Nĕmec J; Soutorová M; Neradilová M; Pohunková D; Zamrazil V; Vána S; Havelka J; Röhling S
    Endocrinol Exp; 1979 Mar; 13(1):53-63. PubMed ID: 316382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Release of patients after therapy with unsealed radionuclides.
    International Commission on Radiological Protection
    Ann ICRP; 2004; 34(2):v-vi, 1-79. PubMed ID: 15571759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liquid discharges from the use of radionuclides in medicine (diagnosis).
    Barquero R; Agulla MM; Ruiz A
    J Environ Radioact; 2008 Oct; 99(10):1535-8. PubMed ID: 18243441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Shielding effect of distance in (131)I-131 therapy for differentiated thyroid cancer].
    Chi X; Liu F; Li G; Wang Q; Deng Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Feb; 34(2):286-8. PubMed ID: 24589615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [I131 in blood samples: management in the laboratory].
    Vialard-Miguel J; Mazère J; Mora S; Georges A; Ducassou D; Corcuff JB
    Ann Biol Clin (Paris); 2005; 63(5):561-5. PubMed ID: 16230298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The evaluation of the external dose measurement of the patients treated with radioiodine therapy.
    Mulazimoglu M; Edis N; Tamam MO; Uyanik E; Ozpacaci T
    Radiat Prot Dosimetry; 2010 Oct; 141(3):233-8. PubMed ID: 20624753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Consensus proposal on the use of 131I in the treatment of thyrotoxicosis and thyroid cancer].
    Michaud P
    Rev Med Chil; 1998 Jul; 126(7):855-65. PubMed ID: 9830780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new proposal for monitoring patients in nuclear medicine.
    Willegaignon J; Guimarães MI; Sapienza MT; Stabin MG; Malvestiti LF; Marone M; Sordi GM
    Health Phys; 2006 Dec; 91(6):624-9. PubMed ID: 17099406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of 131I theory for 2,000 thyrotoxic patients: do the effects depend on the dose?
    Zgliczynski S; Gietka-Czernel M; Gorowski T; Bednarski A; Chomicki O; Jastrzebska W; Makowska A; Niegowska E; Pucilowska J; Soszynski P
    Exp Clin Endocrinol; 1991 May; 97(2-3):286-91. PubMed ID: 1915646
    [No Abstract]   [Full Text] [Related]  

  • 32. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
    Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
    J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [131I-treatment of the autonomous toxic nodule. Assessment of a fixed dose protocol].
    Abós MD; Banzo J; Razola P; García F; Prats E
    Rev Esp Med Nucl; 1999 Dec; 18(6):431-5. PubMed ID: 10611569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
    Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
    J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of a voxel phantom as a source and a second voxel phantom as a target to calculate effective doses in individuals exposed to patients treated with 131I.
    de Carvalho AB; Hunt J; Silva AX; Garcia F
    J Nucl Med Technol; 2009 Mar; 37(1):53-6. PubMed ID: 19223425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Measurement of 131I in the breath of patients treated with 131I].
    Nishizawa K; Ohara K; Oshima M; Maekoshi H; Orito T
    Kaku Igaku; 1977 Jun; 14(3):361-4. PubMed ID: 916371
    [No Abstract]   [Full Text] [Related]  

  • 37. [The treatment of thyroid diseases using 131I in a special ward with a liquid waste storage plant].
    Wellner U; Schicha H
    Nuklearmedizin; 1993 Jun; 32(3):149-55. PubMed ID: 8327334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioiodine treated hyperthyroidism and thyroid carcinoma.
    Appell R; Tsangaris N; Spiegel J
    Am Surg; 1978 Aug; 44(8):537-40. PubMed ID: 707910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient parameters and other radiation safety issues in 131I therapy for thyroid cancer treatment.
    Al-Haj AN; Lagarde CS; Lobriguito AM
    Health Phys; 2007 Dec; 93(6):656-66. PubMed ID: 17993846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring of radioiodine in nuclear medical therapy.
    Heinemann K; Vogt KJ; Friedrich W; Feinendegen LE
    Strahlentherapie; 1983 Aug; 159(8):490-4. PubMed ID: 6623561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.